Full-spectrum flow cytometry Cytek creates a new ecology of multi-color cell analysis and sorting

Recently, the invested company "Cytek Biosciences" of Materia Medica has submitted S-1 and will be listed on Nasdaq

Cytek is headquartered in California, USA.

The development of flow cytometry

In order to successfully cure diseases, people need to have a deep understanding of the billions of cells that make up the human body and their functions

Flow Cytometry (FCM) is a black technology that recognizes cell characteristics.

In 1973, the American BD Company and Stanford University cooperated to develop and produce its first commercial flow cytometer FACS I; in the early 1980s, the first three-color flow cytometer appeared, which enabled the application of flow cytometry The scope gradually expanded; in the mid-1990s, four-color flow cytometry appeared, and flow cytometry gradually entered the central laboratory and laboratory department of the hospital from scientific research units, becoming a part of modern clinical laboratory equipment

For many years, multi-color flow has been regarded as the development trend of flow, but the technology has never really changed

In recent years, with the development of tumor immunotherapy and blood disease diagnosis and treatment, there is an urgent need for multicolor flow detection technology that can accurately detect 20-50 color signals for complex cell analysis

At present, Cytek, invested by Bencao Capital, is the main representative brand of spectral flow cytometry.

Innovative advantages of Cytek flow cytometer

On the technical level, traditional flow cytometers use a combination of dichroic mirrors and filters to distinguish the fluorescence of different wavelengths.

In order to increase the number of multi-color signal acquisition channels and meet the ever-increasing needs of users, Cytek applies optical communication technology to the flow cytometer, which has obvious advantages in cross-over innovation

To put it simply, the full-spectrum flow cytometer represented by Cytek uses CWDM technology to split light, from the application of PMT technology to an avalanche photodiode (Avalanche photodiode, APD) chip technology to complete photoelectric conversion

By introducing optical signal processing technology in the field of optical communication, Cytek flow cytometer can collect full-spectrum signals, and use powerful software algorithms to perform dimensionality reduction or cluster analysis on high-dimensional data, which fundamentally avoids the overlap of fluorescence spectra.

Cytek Aurora Full Spectrum Flow Cytometer: A Breakthrough in Traditional Multicolor Analysis Leader

Cytek precise immunophenotyping: the only one in the world that can perform 40-color analysis of 1 tube of sample

-Cytek Aurora products realize the world's only 1 tube sample 40-color full-spectrum flow analysis, and the research results are published in "Cytometry A";

-Scientists use Cytek products for deep immunophenotyping analysis of main cell subgroups in human peripheral blood, which can accurately identify CD4 T cells, CD8 T cells, regulatory T cells, NK cells, monocytes and dendritic cells, etc.

40 color scheme

Create a new ecology of full-spectrum streaming applications

Through the application of cross-innovation of optical communication technology, combined with epoch-making product line and forward-looking market strategy, Cytek has become the industry's "dark horse" on the industry track to subvert the existing market structure

Application of Cytek Full Spectrum Flow Cytometer

　　Cytek has a technology platform with independent intellectual property rights and continues to develop high and mid-end products, including multi-color flow cytometers such as Aurora-5L, Aurora-3L, Northern Lights, etc.

　　Fame in the First World War-Cytek Aurora Series Full Spectrum Flow Cytometer

　　In 2017, Cytek launched the flagship product Aurora series full-spectrum flow cytometer with original patented technology, which caused a sensation in the field of flow cytometry

　　Aurora is equipped with Cytek's pioneering Full Spectrum Profiling™ (FSP™) technology, which collects full-spectrum fluorescent signals excited by multiple lasers, and easily distinguishes multiple fluorescent markers on a single cell, which significantly improves the sensitivity of high-parameter cell analysis and makes a breakthrough It overcomes the technical limitations of traditional streaming
.
It can be configured with up to 5 lasers, 3 scattered light and 64 fluorescence detection channels, and for the first time to realize the simultaneous collection of high-dimensional signals of 40 colors and above, providing unobstructed viewing angles for phenotypic data collection, breaking the limitation of fluorescent dye combination.
It not only expands the detection capacity, but also simplifies the experimental design, providing users with a better application experience
.

　　Since then, flow cytometry has entered the "high-dimensional era", calmly responding to challenges from user needs
.

　　From the blue-the new generation of spectral flow cytometer Aurora CS comes out

　　Cytek is actively innovating in product research and development, and released another flagship product at the CYTO conference on June 7, 2021-the full-spectrum cell sorter Aurora CS
.

　　Based on the same FSP™ technology, Aurora CS uses a unique optical design and analysis method to improve the flexibility of use, realizes up to 64 levels of gated hierarchical structure sorting, and realizes 6 sorting methods in a 1.
5mL collection tube, 5mL collection Four sorting methods are realized in the tube
.

　　The optical analysis system upgrade of Aurora CS has once again expanded the range of fluorescent dye selection, and there is no need to reset the instrument for each application, which not only enables complex experiments to be realized, but also takes into account the fluency of the user experience
.
The advanced optical system and low-noise electronic system bring ultra-sensitive and high-resolution cell analysis experience, and easily identify cell populations with high autofluorescence or low expression levels of key biomarkers
.

　　Closed-loop product line, all-round multi-color reagent Panel

　　At present, the Cytek Aurora series products are more convenient and economical for users with 1-28 color detection needs; for users with more than 30 color detection needs, Cytek flow cytometer is the only choice
.

　　While providing excellent flow cytometers for the market and users, Cytek insists on independently developing reagent panels with more perfect compatibility
.
Recently, Cytek launched the cFluor™ reagent product series, which has unique spectral characteristics and provides comprehensive biomarker labeling, which can perform deep cell population sorting on human immune cells, greatly assisting scientific research projects
.

　　Cytek forms a complete closed-loop product line by providing a full-system solution of instrument + reagent + software algorithm to improve user experience and increase user stickiness
.

Cytek cFluor ^TM immunoprofiling kit

　　Strong market outlook

　　Cytek Biosciences is headquartered in Silicon Valley, USA, and is committed to the development of innovative flow cytometry technology to provide solutions for life science research and clinical diagnosis and treatment
.
In 2015, Cytek established a branch in Shanghai, namely Shanghai Xiatai, and set up a production base in Wuxi, with sufficient production capacity to meet the needs of global customers
.

　　As a cutting-edge technology leader and a new generation of industry with experience in the research and development of spectroscopy flow cytometry, Cytek has an annual revenue of nearly 100 million U.
S.
dollars and has become a leading spectroscopy flow cytometer company
.

　　In recent years, the clinical market size of flow cytometry is rapidly expanding, and there is a tendency to surpass scientific research
.
Cytek has already started the layout
.
Based on the distribution of streaming users in China, 58% of users are scientific research institutions, and hospitals account for 36.
45%
.
Compared with the conservative strategy of focusing only on the scientific research market, Cytek's "two-pronged approach" for scientific research and clinical development has seized the valuable opportunity to develop the clinical market in the growth period, with a view to covering most clinical markets in the next few years
.

　　At present, a series of Cytek products have been successfully approved by the National Medical Products Administration (CFDA): Northern Lights, a spectroscopic flow cytometer, has been approved for China Medical Device Class II, and the corresponding immune cell subgroup detection reagent has been approved by China Reagent I.
Class certificate, enter the Chinese clinical market
.

　　From the establishment of the company to the upcoming listing, Cytek only took 6 years
.
In the future, it is believed that Cytek will light up the torch of scientific research in the golden age of the vigorous development of life sciences, leverage the market structure, and win the marathon against disease for human health
.

　　Bencao Capital is a specialized fund dedicated to investing in the world's leading life science and medical and health companies, focusing on two major investment directions: innovative medicine and cross-innovative medical devices and diagnostic technologies
.
The core founding team are all overseas biomedicine-related professional doctors, with years of practical accumulation in the pharmaceutical biotechnology industry and more than ten years of successful investment and entrepreneurial experience at home and abroad, as well as professional background, industry experience and international vision
.

　　Bencao Capital is a dual-currency fund manager of RMB and U.
S.
dollars.
It has invested and incubated more than 60 domestic and foreign medical innovation companies.
It has offices in Beijing, Shanghai, and Silicon Valley
.
Bencao Capital adheres to the vision of "achieving a great medical and health company and establishing an international professional investment brand", empowering outstanding entrepreneurial teams and bringing excellent performance returns to investors
.